Business Context and Reporting Period
This Form 8-K is a current report filed by Histogenics Corporation (not Ocugen, Inc.) on July 29, 2015. The filing reports a corporate governance event: the promotion of Stephen Kennedy to Chief Technology Officer and the execution of an amended and restated employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms:
- Base Salary: $320,000 annual gross rate.
- Target Bonus: 35% of the annual base salary.
- Equity Grant: Option to purchase 50,000 shares of Common Stock, subject to board approval.
- Severance: Nine months of base salary and health benefits upon termination without cause or resignation for good reason.
Material Changes
The primary material change is the internal promotion of Stephen Kennedy from Senior Vice President of Technical Operations to Chief Technology Officer. This change is accompanied by a new compensation structure and equity grant vesting over a four-year period, with 25% vesting immediately following the agreement date.
Outlook, Risks, and Contingencies
The filing outlines specific contingencies regarding employment termination:
- Definition of Cause: Includes unauthorized disclosure of confidential information, material breach of agreement, felony conviction, or gross negligence.
- Good Reason Resignation: Defined as material reduction in salary, reduction in authority, relocation over 40 miles, or material breach by the Company.
- Restrictive Covenants: Mr. Kennedy is subject to non-competition and non-solicitation restrictions for 12 months post-employment.
Investor Verification Checklist
- Verify the board of directors' approval of the 50,000 share stock option grant.
- Review the full text of the Amended and Restated Employment Agreement (Exhibit 10.39) for detailed vesting schedules and termination clauses.
- Confirm the company's current cash position to assess the impact of the new salary and potential severance obligations.
- Note the discrepancy between the request metadata (Ocugen, Inc.) and the filing registrant (Histogenics Corporation).